Posts tagged Michael Higgins
Ladenburg starts Flex Pharma at buy; PT $12

Ladenburg Thalmann initiated coverage of Flex Pharma (NASDAQ:FLKS) with a “buy” rating and $12 price target. The stock closed at $4.02 on Jan. 24.

Read More
Roth reinitiates coverage of Savara at buy

Roth Capital Partners reinitiated coverage of Savara (NASDAQ:SVRA) with a “buy” rating and $40 price target. The stock closed at $9.24 on Sept. 26.

Read More
Roth ups Evotec price target to €16

Roth Capital Partners raised its price target for “buy-rated Evotec AG (FSE:EVT) to €16 from €5.50, reflecting a review of the company’s partnered pipeline assets. The stock was recently quoted at €11.66.

Read More
Roth upgrades Cempra to buy

Roth Capital Partners upgraded Cempra (NASDAQ:CEMP) to “buy” and maintained its $8 price target after the company announced positive Phase 3 results in the first of two skin infection (ABSSSI) studies with Taksta. The stock was quoted at $4.20 near midday on Feb. 27.

Read More
Roth starts Arch Therapeutics at buy

Roth Capital Partners initiated coverage of Arch Therapeutics (OTC:ARTH) with a ‘buy” rating and $3 price target. The stock closed at 66 cents on Feb. 13.

Read More
Roth resumes coverage of Palatin, AmpliPhi, Pharming

Roth Capital Partners resumed coverage of Palatin Technologies (NYSE MKT: PTN), AmpliPhi Biosciences (NYSE MKT:APHB) and Pharming Group NV (OTC:PHGUF) with “buy” and price targets of $1.50, $3 and €1.50, respectively.

Read More
Roth reinitiates coverage of Cempra at buy

Roth Capital Partners has reinitiated coverage of Cempra (NASDAQ:CEMP) with a “buy” rating and $37 price target. The stock closed at $19.48 on Monday.

With impressive pivotal studies on solithromycin (Solitaire-IV and Solitaire-Oral), we encourage investors to accumulate a position in Cempra as the company leverages its clinical data in treating community acquired bacterial pneumonia (CABP), including the increasing number of drug-resistant strains,” writes analyst Michael Higgins.

Read More